Bio-Rad Laboratories
(BIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 507,329 | 450,133 | 425,728 | 413,251 | 424,593 |
| Marketable Securities | 278,749 | 277,513 | 284,958 | 284,384 | 277,985 |
| Receivables | 341,548 | 354,161 | 342,223 | 377,640 | 354,401 |
| Inventories | 512,736 | 500,975 | 478,375 | 470,997 | 516,047 |
| Other current assets | 154,054 | 159,146 | 170,560 | 61,747 | 0 |
| TOTAL | $1,794,416 | $1,741,928 | $1,701,844 | $1,716,367 | $1,764,445 |
| Non-Current Assets | |||||
| PPE Net | 433,822 | 439,644 | 428,300 | 428,836 | 420,897 |
| Investments And Advances | 663,533 | 541,732 | 400,262 | 389,309 | 364,129 |
| Intangibles | 728,608 | 751,784 | 746,392 | 754,669 | 786,981 |
| Other Non-Current Assets | 46,017 | 50,255 | 49,398 | 52,097 | 49,572 |
| TOTAL | $1,871,980 | $1,783,415 | $1,624,352 | $1,624,911 | $1,621,579 |
| Total Assets | $3,666,396 | $3,525,343 | $3,326,196 | $3,341,278 | $3,386,024 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 379 | 268 | 264 | 265 | N/A |
| Accounts payable and accrued liabilities | 268,228 | 0 | 0 | 128,608 | 126,640 |
| Accrued Expenses | N/A | 239,847 | 250,813 | 153,426 | 148,283 |
| Other current liabilities | 144,007 | 138,541 | 133,879 | 102,581 | 202,990 |
| TOTAL | $435,235 | $403,894 | $416,882 | $446,761 | $503,783 |
| Non-Current Liabilities | |||||
| Long Term Debt | 435,728 | 435,660 | 435,661 | 435,710 | 435,739 |
| Deferred Revenues | N/A | N/A | N/A | 26,716 | N/A |
| Other Non-Current Liabilities | 111,060 | 114,933 | 275,140 | 118,735 | 269,772 |
| TOTAL | $801,432 | $762,552 | $710,801 | $709,362 | $705,511 |
| Total Liabilities | $1,236,667 | $1,166,446 | $1,127,683 | $1,156,123 | $1,209,294 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,305 | 29,162 | 29,134 | 29,102 | 28,960 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 1,758,573 | 1,741,203 | 1,712,780 | 1,694,962 | 1,655,925 |
| Other shareholders' equity | 379,279 | 331,946 | 207,345 | 218,844 | 260,937 |
| TOTAL | $2,429,729 | $2,358,897 | $2,198,513 | $2,185,155 | $2,176,730 |
| Total Liabilities And Equity | $3,666,396 | $3,525,343 | $3,326,196 | $3,341,278 | $3,386,024 |